August 2007
Worldwide Biotech;Aug2007, Vol. 19 Issue 8, p2
Trade Publication
The article reports that the Ampligen Phase IIB trial for influenza was initiated by the Hemispherx Biopharma, Inc. in Australia. The Japanese National Institute of Infectious Diseases (JIID) reported robust immune responses in animals when Ampligen (r) was added to either avian or seasonal influenza vaccines which prompted the research of TLR3 ligand Ampligen (r). The U.S. Food and Drug Administration (FDA) announced new guidelines for influenza vaccines and adjuvants such as TLR3 ligands.


Related Articles

  • HEMISPHERX COMPLETES ENROLLMENT IN PHASE II AMPLIGEN STUDY.  // Worldwide Biotech;Jul2008, Vol. 20 Issue 7, p8 

    The article reports the start of Phase II clinical trial of Ampligen (r) as seasonal flue vaccine enhancer has been completed by Hemispherx Biopharma Inc. in Australia. The company will evaluate the safety and efficacy of Ampligen (r) as an enhanser for seasonal flu vaccine. The secondary goal...

  • CLINIC ROUNDUP.  // BioWorld Today;6/3/2008, Vol. 19 Issue 107, p12 

    This section offers news briefs on clinical trials of various drugs as of June 2008. AMAG Pharmaceuticals Inc. reported positive results from two Phase III studies of ferumoxytol as iron replacement therapeutic agent in patients with chronic kidney disease with functioning kidney transplants....

  • Chronic tonic.  // Pharmaceutical Executive;May98, Vol. 18 Issue 5, p134 

    Announces a Phase III clinical study of Hemispherx Biopharma's clinical study of its drug Ampligen. Details on the placebo-controlled study; Results of earlier trial.

  • Influenza pandemic vaccines: how to ensure a low-cost, low-dose option. Stöhr, Klaus; Kieny, Marie-Paule; Wood, David // Nature Reviews Microbiology;Aug2006, Vol. 4 Issue 8, p565 

    Global access to an effective influenza vaccine will be essential in the event of a pandemic. Here, the WHO's Klaus Stöhr, Marie-Paule Kieny and David Wood argue that assessing the clinical benefits of low-dose H5N1 vaccines in animal models is crucial to achieving this goal.

  • U.S. Patent Disclosures.  // BioWorld Today;8/15/2011, Vol. 22 Issue 157, p4 

    The article announces the granting of U.S. patents for biotechnology firms in 2011. Alethia Biotherapeutics Inc. received a patent for "Polynucleotide and Polypeptide Sequences Involved in the Process of Bone Remodeling." Convergen LifeSciences was given a patent for the CNVN202 targeted...

  • FDA AUTHORIZES ALFERON LDO STUDY FOR FLU PREVENTION.  // Biotech Business;Feb2011, Vol. 24 Issue 2, p6 

    The article announces the decision of the U.S. Food and Drug Administration (FDA) to lift the clinical hold it placed on the Phase II double-blind randomized trial of Alferon LDO oral interferon alfa-n3 from Hemispherx Biopharma Inc. for the prevention and treatment of influenza. A review of a...

  • Ampligen & Chronic Fatigue. Klotter, Jule // Townsend Letter for Doctors & Patients;Aug/Sep2005, Issue 265/266, p24 

    Explains that Hemispherx Biopharma, Inc. has completed a Phase III Chronic Fatigue Syndrome (CFS) trial of Ampligen, a double-stranded RNAdrug. Modulation of the immune system; Antiviral agent; Randomized, double-blind, placebo-controlled, crossover study of 234 subjects; Treadmill exercise...

  • Hemispherx Biopharma expands SARS initiative.  // PharmaWatch: Biotechnology;December 2003, Vol. 2 Issue 12, p9 

    Introduces new drug delivery formats of Alferon N and Ampligen, lead compounds developed by Hemispherx Biopharma Inc. Clinical indications of the drugs; Description of Alferon N and Ampligen; Presentation of the clinical trial of the drugs.

  • Clinic Roundup.  // BioWorld Today;7/20/2010, Vol. 21 Issue 138, p5 

    This section offers news briefs on clinical trials. Positive results were obtained by Aegera Therapeutics Inc. from the Phase I portion of its trial of AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma or primary liver cancer. The first participant was...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics